Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash Items
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Cash from Investing Activities: 2023-2025

Historic Cash from Investing Activities for BioLineRx (BLRX) over the last 2 years, with Jun 2025 value amounting to -$3.7 million.

  • BioLineRx's Cash from Investing Activities rose 57.15% to -$3.7 million in Q2 2025 from the same period last year, while for Jun 2025 it was $9.5 million, marking a year-over-year increase of 214.47%. This contributed to the annual value of $29.4 million for FY2024, which is 1934.21% up from last year.
  • Per BioLineRx's latest filing, its Cash from Investing Activities stood at -$3.7 million for Q2 2025, which was up 54.70% from -$8.2 million recorded in Q1 2025.
  • BioLineRx's Cash from Investing Activities' 5-year high stood at $16.7 million during Q1 2024, with a 5-year trough of -$20.4 million in Q4 2023.
  • For the 3-year period, BioLineRx's Cash from Investing Activities averaged around $1.9 million, with its median value being $5.4 million (2023).
  • Data for BioLineRx's Cash from Investing Activities shows a peak YoY increase of 154.70% (in 2024) and a maximum YoY decrease of 177.88% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows BioLineRx's Cash from Investing Activities stood at -$20.4 million in 2023, then surged by 154.70% to $11.2 million in 2024, then skyrocketed by 57.15% to -$3.7 million in 2025.
  • Its last three reported values are -$3.7 million in Q2 2025, -$8.2 million for Q1 2025, and $11.2 million during Q4 2024.